| 2016-10-19 05:53:32|
Q, CRL… 05:53 10/19 10/19/16
Quintiles downgraded to Hold from Buy at Jefferies
Jefferies analyst David Windley downgraded Quintiles (Q) to Hold citing concern over the revenue synergy targets from the IMS merger. Windley notes that his firm's survey work indicates sponsors remain skeptical of IMS data's value in speeding clinical trial execution. He lowered his price target for the shares to $79 from $80. The analyst's top picks in Pharmaceutical Services are Charles River (CRL), INC Research (INCR) and PRA Health (PRAH).